Wave Crashes Down On Duchenne Fail
Suvodirsen Terminated After Negative Trial
Having spectacularly failed even to match Sarepta’s Exondys 51 in the restoration of dystrophin in Duchenne muscular dystrophy patients, Wave's future is dependent on soon-to-be published data on a Huntington’s disease therapy.
You may also be interested in...
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
The UK firm has tapped into EU funds through an Irish subsidiary to advance its treatment for acute respiratory distress syndrome based on a reformulation of Novartis's Gleevec.